(Q37997237)

26 August 2017

Novel biomarkers in chronic heart failure (English)

1 reference

26 August 2017

0 references

0 references

chronic heart failure

1 reference

inferred from title

author

Christopher M O'Connor

series ordinal

4

object named as

Christopher O'Connor

1 reference

26 August 2017

3

G Michael Felker

1 reference

26 August 2017

Tariq Ahmad

1

1 reference

PubMed ID

22450126

26 August 2017

Mona Fiuzat

series ordinal

2

1 reference

PubMed ID

22450126

26 August 2017

language of work or name

English

0 references

publication date

27 March 2012

1 reference

Nature Reviews Cardiology

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

6

1 reference

26 August 2017

347-359

1 reference

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

26 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

The "Modern" View of Heart Failure: How Did We Get Here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

B-type natriuretic peptide -- a window to the heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Emerging biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic value of biomarkers in heart failure: application of novel methods in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Adrenomedullin: potential in physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Regulation of cardiac adrenomedullin in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

The neuregulin-I/ErbB signaling system in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulin signaling and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulin-1β for the treatment of systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Identification of serum soluble ST2 receptor as a novel heart failure biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

ST2: a novel remodeling biomarker in acute and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Biomarkers of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Biomarker guided therapy for heart failure: focus on natriuretic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Troponin elevation in heart failure prevalence, mechanisms, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Biomarkers as surrogate end points in heart failure trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Galectin-3: a novel mediator of heart failure development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Novel biomarkers in cardiovascular disease: update 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neurohormonal activation in congestive heart failure and the role of vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Vasopressin antagonism in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Upregulation of aquaporin-2 water channel expression in chronic heart failure rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Hemodynamic effects of infused arginine vasopressin in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Possible vascular role of increased plasma arginine vasopressin in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Cystatin-C and mortality in elderly persons with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Clinical outcome of renal tubular damage in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Renal biomarkers of kidney injury in cardiorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Multimarker approach for heart failure management: perspectives and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Use of multiple biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Assessing the Incremental Role of Novel and Emerging Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Systems biology of heart failure, challenges and hopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

The Seattle Heart Failure Model: prediction of survival in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Validity of clinical diagnosis of heart failure in primary health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Adrenomedullin: an autocrine/paracrine factor for cardiorenal protection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Elevation of circulating and ventricular adrenomedullin in human congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Increased plasma levels of adrenomedullin in patients with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Evaluation of high-sensitivity assays for cardiac troponin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Galectin-3 in heart failure: high levels are associated with all-cause mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Prognostic value of plasma endothelin-1 in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Impact of myocardial function on cystatin C measurements in chronic systolic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Cystatin C: a step forward in assessing kidney function and cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Assessing New Biomarkers and Predictive Models for Use in Clinical Practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Biomarker-guided treatment of heart failure: still waiting for a definitive answer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

Determining decision limits for new biomarkers: clinical and statistical considerations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.37

The limited reliability of physical signs for estimating hemodynamics in chronic heart failure

31 March 2020

1 reference

12 December 2020

Risk stratification in heart failure using artificial neural networks

1 reference

12 December 2020

Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure

1 reference

12 December 2020

Biological variation of cystatin C: implications for the assessment of glomerular filtration rate.

1 reference

12 December 2020

The stress hormone copeptin: a new prognostic biomarker in acute illness

1 reference

12 December 2020

Neuregulin-1 and its potential role in the control of cardiac function

1 reference

12 December 2020

Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2012.37

1 reference

26 August 2017

1 reference

PubMed ID

22450126